Oxford Biomedica partner delays Parkinson's disease treatment trial

Oxford stated patient-level data from Axovant Gene Therapies' second cohort study into SUNRISE-PD had demonstrated "consistent, clinically meaningful outcomes" and evidence of dose-response.

However, Oxford Biomedica said the development of a suspension-based manufacturing process would take longer than initially anticipated as a result of data and finishing issues.

Axovant now anticipates that a randomised, sham-controlled trial would likely be unable to enrol patients before the end of 2021.

In June 2018, Oxford Biomedica out-licensed OXB-102, later renamed AXO-Lenti-PD, to Axovant through an $842.5m worldwide licence agreement, with a three-year clinical supply agreement later being signed in July 2020.

As of 0845 GMT, Oxford shares were down 0.47% at 812.18p.